Stocks and Investing
Stocks and Investing
Thu, December 17, 2020
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Wed, December 16, 2020
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Vikram Purohit Maintained (TBPH) at Buy with Decreased Target to $31 on, Dec 16th, 2020
Vikram Purohit of Morgan Stanley, Maintained "Theravance Biopharma, Inc." (TBPH) at Buy with Decreased Target from $32 to $31 on, Dec 16th, 2020.
Vikram has made no other calls on TBPH in the last 4 months.
There are 2 other peers that have a rating on TBPH. Out of the 2 peers that are also analyzing TBPH, 0 agree with Vikram's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Vikram
- Liisa Bayko of "Evercore ISI Group" Initiated at Buy and Held Target at $30 on, Tuesday, November 24th, 2020
- Geoffrey Porges of "SVB Leerink" Maintained at Buy with Decreased Target to $35 on, Friday, November 6th, 2020
Contributing Sources